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Candida albicans biofilm formation is an important virulence factor in the pathogenesis of disease, 
a characteristic which has been shown to be heterogeneous in clinical isolates. Using an unbiased 
computational approach we investigated the central metabolic pathways driving biofilm heterogeneity. 
Transcripts from high (HBF) and low (LBF) biofilm forming isolates were analysed by RNA sequencing, 
with 6312 genes identified to be expressed in these two phenotypes. With a dedicated computational 
approach we identified and validated a significantly differentially expressed subnetwork of genes 
associated with these biofilm phenotypes. Our analysis revealed amino acid metabolism, such as 
arginine, proline, aspartate and glutamate metabolism, were predominantly upregulated in the HBF 
phenotype. On the contrary, purine, starch and sucrose metabolism was generally upregulated in 
the LBF phenotype. The aspartate aminotransferase gene AAT1 was found to be a common member 
of these amino acid pathways and significantly upregulated in the HBF phenotype. Pharmacological 
inhibition of AAT1 enzyme activity significantly reduced biofilm formation in a dose-dependent manner. 
Collectively, these findings provide evidence that biofilm phenotype is associated with differential 
regulation of metabolic pathways. Understanding and targeting such pathways, such as amino acid 
metabolism, is potentially useful for developing diagnostics and new antifungals to treat biofilm-based 
infections.
Candida bloodstream infections (CBSI) are the third most frequent infection in intensive care units and are 
associated with unacceptable rates of morbidity and mortality (up to 50%)1,2, as well as high healthcare costs3–5. 
The presence of indwelling devices, such as central venous catheters, profoundly impacts these associated prob-
lems. Moreover, poor patient prognosis is impacted by delayed diagnostics and limited antifungal options6. The 
recalcitrant nature of biofilms reduces the effectiveness of antifungal regimens, thereby complicating the clinical 
management of CBSI7. Candida albicans is the most prevalent and pathogenic of the Candida species involved in 
CBSI, which is typified by its capacity to form robust biofilms. Therefore, identifying the molecular mechanisms 
that contribute to C. albicans biofilm formation and developing new strategies to prevent CBSI is vital for mini-
mising mortality rates and healthcare costs.
C. albicans is an opportunistic pathogen that frequently uses the biofilm lifestyle as a mode of protection 
against the host immune system and chemotherapeutic intervention. C. albicans capacity for physiological 
adaptation permits nutrient assimilation and growth in a variety of host environments8. A key component of C. 
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albicans adaptation is filamentous growth, which is stimulated by a variety of environmental and physiological 
factors, including the carbohydrate source, amino acid starvation, hypoxia, elevated levels of CO2, pH and tem-
perature8–10. Metabolic adaptation to such conditions, as well as antifungal agents and stress conditions, promote 
C. albicans pathogenicity, which includes yeast-hypha morphogenesis, phenotypic switching, adhesins, invasins, 
and secreted hydrolases8, factors all important to the biofilm phenotype11. In fact, these biofilm related processes 
are driven by six key transcriptional regulators as part of a complex transcriptional circuitry12. While this level of 
global control is understood, how these relate to central metabolic processes is limited. Although several anabolic 
and catabolic pathways, such as those involved in carbon and amino acid metabolisms, have been shown to play a 
pivotal role in C. albicans pathogenicity, the key pathways associated with biofilm formation remain unclear13,14.
It has recently been shown that biofilm forming ability of candidaemia isolates, and the choice of antifungal 
drug used for treatment, is significantly associated with patient mortality15,16. Subsequent studies by our group 
identified that the biofilm phenotype is heterogeneous, and stratification of clinical isolates as either high- or 
low- biofilm formers (HBF and LBF) has been shown to be a good predictor of clinical outcomes, where the HBF 
were shown to significantly correlate with mortality, unlike LBF17. While significant and elegant efforts have been 
made to unravel the mechanisms of biofilm formation12, these have been limited to laboratory strains, which 
have limited resemblance to the biological heterogeneity exhibited by clinical isolates16,17. Therefore, there is solid 
rationale to use clinically derived strains for studies that can explain why certain clinical C. albicans biofilms grow 
to be much more pathogenic (HBF) than others (LBF).
In this study, we evaluated the hypothesis that metabolic adaptation plays an important role in C. albicans 
biofilm heterogeneity, where differential expression of certain C. albicans genes or pathways is the primary factor 
that separates the LBF from the HBF. To do so, we performed a comparative RNA sequencing (RNA-Seq) analysis 
on samples derived from the bloodstream isolates of candidaemia patients, which were previously identified to 
be HBF or LBF. To put our results from the differential expression analysis into a biologically-interpretable and 
metabolic context, we first created a global network of interacting C. albicans genes by combining all C. albicans 
pathway maps in the KEGG database18. In this global network, in order to highlight the region that shows the 
strongest differential expression, we used a bioinformatics workflow that identifies the subnetwork of the most 
significantly differentially expressed genes between the LBF and HBF. This network-based approach has been 
shown to recover relevant biological pathways that were significantly deregulated in single-species as well as 
multi-microbial communities19,20.
To validate our computational findings experimentally, we selected four genes from the identified subnetwork, 
and performed real-time quantitative PCR (qPCR) experiments. Using qPCR, the increase or the decrease in the 
expression of these four genes in the HBF was confirmed using a different set of clinical isolates. Furthermore, we 
performed an inhibition experiment using the AAT1 gene, a central node in the subnetwork involved in several 
amino acid pathways, to evaluate the effect of its inhibition on biofilm formation and C. albicans survival. Overall, 
this study addresses a major gap in our understanding of the metabolic pathways and their role in clinically 
important C. albicans biofilm entity. Elucidating this essential element of pathogenesis provides invaluable infor-
mation to identify metabolic biomarkers for early biofilm diagnostics and paves the way for the development of 
personalised therapeutic strategies.
Results
RNA-Seq analysis. In order to identify the differentially expressed genes between the C. albicans LBF and 
HBF, we performed a comparative RNA-Seq analysis on pre-characterised clinical isolates17. Sequencing the 
transcriptome of these six samples (each isolate in triplicate) resulted in nearly 141 million raw RNA-Seq reads 
(Table 1). Following quality control and filtering reads from non-coding RNAs, a high percentage of raw reads 
was mapped to the C. albicans genome (87.4% and 95% of LBF and HBF reads, respectively). The percentage of 
reads that were mapped to the regions of the genome annotated with KEGG genes21, was also high in both LBF 
(66%) and HBF (74%), indicating that the coding genome regions were mostly covered with the genes in our 
database. Out of 7281 genes, 6312 were found to be expressed in both conditions, among which 1007 and 783 
were significantly upregulated (P < 0.05) with a minimum 2-fold change in the LBF and HBF, respectively (Fig. 1).
An overview of differentially expressed functions. To obtain an overview of functional differences, 
we categorised the genes that showed a minimum 2-fold upregulation (P < 0.05) in their expression in the LBF 
(1007) and HBF (783) into Gene Ontology processes22 (Supp. Fig. 1). These functional categories included a 
range of processes including filamentous growth, biofilm formation, cellular transport, response to stress, and 
pathogenesis.
Nr. of 
samples
Nr. of raw 
reads
% of 
reads 
after QC
% reads 
after t/rRNA 
removal
% mapped 
reads to 
genome
% mapped 
reads to 
KEGG genes
All samples 6 140,631,025 99.32 97.80 91.40 70.34
LBF 3 68,484,992 98.75 96.14 87.40 66.21
HBF 3 72,146,033 99.86 99.38 95.20 74.26
Table 1.  The vast majority of reads in both low (LBF) and high biofilm formers (HBF) passed the quality 
control. A large portion was mapped to the KEGG genes that were used to annotate the C. albicans genome. 
Percentages are relative to the number of raw reads.
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In both the LBF and HBF, the biofilm formation process represented only 4% of the number of significantly 
upregulated genes (Supp. Fig. 1). However, when certain genes in this functional category were investigated, 
those associated with a yeast state were found to be upregulated in the LBF (YWP1, log2 fold change = 8.6; NRG1, 
log2 fc = 3.7), whereas the HBF had hyphal specific gene expression increased (HWP1, log2 fc = 6; HYR1, log2 
fc = 3.8; and ALS3, log2 fc = 2.8). These expression patterns are consistent with the yeast and hyphal phenotypes 
presented in LBF and HBF, respectively. Similar to the biofilm formation process, there was no difference in the 
percentage of upregulated genes associated with cell adhesion and hyphal growth in the LBF and HBF, which in 
total accounted for only 4% of upregulated genes in each group.
The three functional groups that contained the greatest number of significantly upregulated genes were trans-
port, response to chemicals, and response to stress, which accounted for 52% (LBF) and 48% (HBF) of the total 
number of genes analysed for this section (1790). In the LBF, the greatest change in expression, namely 21%, 
was found in genes related to stress response (Fig. 1B). Genes associated with cellular transport were the mostly 
up-regulated ones in the HBF, accounting for 20% of genes (Supp. Fig. 1). A common limitation of differential 
gene expression analyses is the human bias for investigating the genes related to preconceived hypotheses and 
those reported in the existing literature. An expected finding was the higher expression of HWP1 in the HBF, as 
this is a hyphal-specific gene known to be involved in biofilm formation23,24. Reciprocally, the yeast wall protein 
(YWP1) was significantly upregulated in the LBF isolates. Cells lacking this are more adhesive and can form 
thicker biofilms25. Moreover, we identified ECE1 was significantly upregulated (log2 6-fold) in the HBF, which 
codes for the novel candidalysin peptide toxin that has recently been reported to induce epithelial cell dam-
age26. SAP8 was also upregulated in the HBF phentotype, which is a protease previously identified to be highly 
expressed in mature biofilms of denture stomatitis patients27. Additionally, a glucose transporter gene, HGT9, was 
also upregulated in the HBF, and from studies we know that glucose has a direct effect on C. albicans adhesion 
and biofilm formation28. Therefore, the upregulation of HGT9 expression found in this study may be due to the 
increased utilisation of carbon sources in HFB isolates. Despite these potential genes of interest, we identified a 
large number of other genes (n = 1790) that were differentially expressed between the LBF and HBF, which is in 
line with other RNA-Seq studies looking at differentially expressed genes in C. albicans planktonic cells compared 
to those grown in a biofilm (n = 1599)12. While we can manually try and make sense of the biological data one 
gene at a time, our ability to decipher what the global impact of all the changes mean in the context of one another 
is limited.
In this analysis, many genes are grouped into a single functional category and some genes are even associated 
with multiple categories, making this a very coarse-grained approach. The HWP1 example shows that only look-
ing at the high level categories does not help gain an understanding of the key players involved, and may indeed 
lead to a biased approach to analysis through selection of perceived biofilm related genes. Hence, this type of 
analysis is less suitable for pinpointing the most important factors in the metabolic network that contribute to 
biofilm heterogeneity.
Network analysis identifies the significant changes. In order to obtain a more informative, accurate 
picture of the mechanisms involved in C. albicans biofilm formation, we performed a computational analysis that 
takes into account the full network of C. albicans pathways present in the KEGG database. This approach is able 
to identify the most significantly differentially expressed parts in this full network, and can be summarised in 
three main steps: i) constructing a global pathway map of interacting genes, ii) assigning a positive or a negative 
numerical score to each gene in the network, which reflects the significance of the gene’s differential expression, 
and iii) applying a search algorithm on the score-annotated network for identifying the maximum-scoring sub-
network. This subnetwork corresponds to the region in the global network where the (interacting) genes with the 
most significant differential expression are located.
Figure 1. Differential expression of C. albicans genes in the low (LBF) and high biofilm formers (HBF) 
groups. Log fold changes are plotted against the log mean expression of 6312 C. albicans genes. The blue and red 
dots denote the genes that were upregulated by a minimum 2-fold change in expression (P < 0.05) in the LBF 
(1007) and HBF (783) respectively.
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To this end, we integrated 104 C. albicans-specific KEGG pathway maps that contain the molecular interaction 
and reaction gene networks for functional categories, including metabolism, genetic and environmental informa-
tion processing and cellular processes into a single, global C. albicans gene network (2960 genes). After removing 
the genes that did not interact with any other genes from the network, the global network consisted of 1721 nodes 
(genes) and 8197 undirected edges (gene interactions).
Taking the overlap between the genes that were expressed in both LBF and HBF samples with those in the 
global C. albicans network resulted in a final network of 859 genes and 1997 gene interactions. Next, we used a 
strict P value threshold of 10−10: genes in the network with smaller P values were assigned positive scores, while 
genes with larger P values were assigned negative scores (see Methods). Correspondingly, we assigned 59 of 859 
genes in the network positive (node) scores, while the rest of the genes attained negative scores. The Heinz net-
work search algorithm was applied on the network to calculate the maximum-scoring sub-network as described 
elsewhere20. The identified subnetwork consisted of 39 genes (Supp. Table), of which 20 were down- and 19 were 
upregulated in the HBF (Fig. 2). The total number of pathways associated with these genes was 41 (Table 2), 
among which (i) arginine and proline metabolism, (ii) pyruvate metabolism and (iii) fatty acid metabolism were 
predominantly upregulated in the HBF samples (Fig. 2). In contrast, purine metabolism and starch and sucrose 
metabolism were mostly up-regulated in the LBF samples (Fig. 2).
Validation of RNA-Seq results. To validate the findings from our RNA-Seq analysis, we performed 
real-time quantitative PCR (qPCR) on 9 additional HBF and LBF isolates for four genes, AAT1, ACC1, SAD1 
and XOG1, which are members of the key KEGG pathways that were found by our network analysis (Fig. 3). Two 
of the selected genes, SAD1 and XOG1, involved in amino acid and sugar metabolism, respectively, were signif-
icantly upregulated (P < 0.05) in the LBF. AAT1 and ACC1, involved in amino acid and fatty acid metabolism, 
respectively, were upregulated (P < 0.05) in the HBF. For all selected genes, qPCR results were in agreement with 
the results from the RNA-seq analysis (Fig. 3): the expression levels of SAD1 and XOG1 were found to be 3-fold 
(P < 0.001) and 2-fold (P < 0.05) upregulated in the LBF. Furthermore, both AAT1 and ACC1 were found to be 
significantly upregulated by 3-fold in the HBF (P < 0.05 and P < 0.01, respectively).
Figure 2. The maximum-scoring subnetwork identified in the global C. albicans metabolic network. 
The subnetwork corresponds to the region in the global metabolic gene network where the most significantly 
differentially expressed genes between the LBF and HBF are located. The colours red and blue with gene names 
denote the fold change (upregulation in HBF and LBF, respectively). Different coloured lines indicate different 
metabolic pathways (labelled near each pathway). This computationally-identified subnetwork suggests the 
aspartate aminotransferase (AAT1) to be a key player in biofilm heterogeneity. Moreover it highlights the 
importance of amino acid metabolic pathways.
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AAT1 drives the biofilm phenotype. The maximum-scoring subnetwork identified by our bioinformatic 
workflow highlighted an overall upregulation of genes in different amino acid metabolism pathways in the HBF, 
therefore, these genes were investigated further. The gene AAT1, coding for aspartate aminotransferase, which 
plays a central role in different amino acid metabolism pathways, was found to be significantly upregulated in 
the HBF (Fig. 2). The impact of inhibition of the AAT enzyme activity by the aminoxy acetate (AOA) inhibitor 
on C. albicans biofilm formation was then examined. At all tested concentrations, AOA had no toxic effect on 
C. albicans growth. Next, biofilm formation by the HBF (n = 6) in the presence of different concentrations of AOA 
was assessed. There was significant reduction in biofilm formation in the presence of AOA in a dose dependant 
KEGG 
Pathway ID
Cumulative 
pathway score Pathway name Gene IDs
cal00330 198.9823 Arginine and proline metabolism cal:CaO19.13487,AAT1,CBP1,AFP99,AFP98
cal00230 132.1469 Purine metabolism YND1, AMD1, CDC19, PRI1, DPB3, cal:CaO19.14031,
cal00500 110.8155 Starch and sucrose metabolism GLK3, MAL2, GSY1, TPS2, GDB1, cal:CaO19.14031, XOG1
cal00410 104.9783 beta-Alanine metabolism cal:CaO19.13487, CBP1, AMO2
cal00250 59.83122 Alanine, aspartate and glutamate metabolism ASP1, AAT1, AGX1, GFA1, URA2
cal04146 56.56852 Peroxisome FAA21, CaJ7_0483, AGX1
cal03030 54.2462 DNA replication PRI1, DPB3
cal00071 54.03803 Fatty acid degradation FAA21, CaJ7_0483, cal:CaO19.13487, SAD1
cal00061 43.38386 Fatty acid biosynthesis FAA21, CaJ7_0483, ACC1, FAS1
cal00350 42.3465 Tyrosine metabolism AAT1, SAD1, AMO2
cal00360 39.59607 Phenylalanine metabolism AAT1, AMO2
cal00400 36.1654 Phenylalanine, tyrosine and tryptophan biosynthesis AAT1
cal00270 28.13576 Cysteine and methionine metabolism AAT1, MDH2
cal00520 24.9472 Amino sugar and nucleotide sugar metabolism GLK3, GFA1, cal:CaO19.14031
cal00240 23.8103 Pyrimidine metabolism YND1, PRI1, DPB3, URA2
cal00564 21.70483 Glycerophospholipid metabolism PSD1, CHO1, OPI3, CRD1, cal:CaO19.12881
cal00030 20.34725 Pentose phosphate pathway RKI1, PFK2, cal:CaO19.14031
cal00460 12.2906 Cyanoamino acid metabolism ASP1
cal03420 11.9899 Nucleotide excision repair DPB3
cal03410 11.9899 Base excision repair DPB3
cal03018 2.67299 RNA degradation PFK2
cal00051 − 2.79647 Fructose and mannose metabolism GLK3, PFK2
cal00561 − 5.29207 Glycerolipid metabolism cal:CaO19.13487, cal:CaO19.12881, TGL2
cal00020 − 8.02964 Citrate cycle (TCA cycle) MDH2
cal00565 − 8.28607 Ether lipid metabolism cal:CaO19.12881
cal00100 − 8.28607 Steroid biosynthesis cal:CaO19.12881
cal00590 − 8.28607 Arachidonic acid metabolism cal:CaO19.12881
cal00592 − 8.28607 alpha-Linolenic acid metabolism cal:CaO19.12881
cal00260 − 9.61059 Glycine, serine and threonine metabolism CHO1, AGX1, AMO2
cal00640 − 15.0766 Propanoate metabolism ACS1, ACC1
cal00040 − 15.1134 Pentose and glucuronate interconversions cal:CaO19.13487
cal00280 − 15.1134 Valine, leucine and isoleucine degradation cal:CaO19.13487
cal00053 − 15.1134 Ascorbate and aldarate metabolism cal:CaO19.13487
cal00340 − 15.1134 Histidine metabolism cal:CaO19.13487
cal00310 − 15.1134 Lysine degradation cal:CaO19.13487
cal00380 − 15.1134 Tryptophan metabolism cal:CaO19.13487
cal00680 − 16.4076 Methane metabolism ACS1, AGX1, PFK2
cal00052 − 24.6707 Galactose metabolism GLK3, MAL2, PFK2, cal:CaO19.14031
cal00630 − 32.8304 Glyoxylate and dicarboxylate metabolism MDH2, AGX1, MLS1
cal00010 − 36.1765 Glycolysis/Gluconeogenesis GLK3, ACS1, cal:CaO19.13487, CDC19, SAD1, PFK2, cal:CaO19.14031
cal00620 − 59.867 Pyruvate metabolism ACS1, cal:CaO19.13487, ACC1, CDC19, MDH2, MAE1, MLS1
Table 2.  KEGG pathways that are associated with the genes in the maximum-scoring sub network. The 
cumulative score is the sum of the scores of genes in the pathway that were found in the maximum-scoring sub 
network.
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manner (Fig. 4A), confirming an apparent role of AAT in biofilm formation. Conversely, no significant reduction 
in biofilm biomass was found with LBF isolates (n = 5) in the presence of AOA (Supp. Fig. 3). Analysis of the 
biofilm phenotype by scanning electron microscopy showed striking differences with more yeast and pseudohy-
phal cells with AOA treatment compared to the filamentous multidimensional architecture in untreated controls 
(Fig. 4B). This suggests that AAT plays a role in modulating biofilm formation via regulating filamentation and 
morphogenesis in C. albicans. Furthermore, biochemical assessment of secreted AAT levels with different clin-
ical isolates confirmed that a significantly higher level of AAT was produced by HBF compared to LBF biofilms 
(Fig. 5).
Discussion
Understanding the molecular mechanisms involved in the phenotypic differences between C. albicans clinical 
isolates is an important avenue of investigation for developing and improving clinical management strategies, 
Figure 3. Validation of RNA-seq data. Expression of selected genes (AAT1, ACC1, SAD1 and XOG1) was 
assessed by qPCR analysis of RNA isolated from 24 h biofilms of 9 HBF and 9 LBF clinical isolates. Graphs show 
percentage expression of each gene compared to a housekeeping gene ACT1. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 4. Inhibition of AAT activity reduces biofilm formation. C. albicans biofilms (n = 6) were formed in 
the presence of serially diluted AOA (Aminoxy acetate [AAT inhibitor]), concentration range from 0–400 mg/L. 
After 24 h incubation, biofilm biomass was assessed by crystal violet (CV) assay. (A) Graph shows CV 
absorbance. *P < 0.05, **P < 0.01. (B) Biofilms grown on thermonox coverslips in the presence or absence of 
400 mg/L of AOA were fixed and processed for scanning electron microscope imaging. Micrographs show the 
biofilm phenotype at 1000x and 3000x magnification.
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both in terms of antifungal therapy and the development of new diagnostic strategies. We previously reported 
that C. albicans biofilm heterogeneity is an important clinical entity17, and that extracellular DNA (eDNA) 
release contributes to biofilm-associated antifungal resistance29. However, this somewhat targeted investigational 
approach fails to take into account the global factors driving these paradoxical phenotypes that we observe clin-
ically. Here, we identified the differential expression of several metabolic pathways that potentially contribute 
to C. albicans biofilm heterogeneity. This study is the first to use an integrated KEGG pathway analysis to reveal 
biologically important pathways in C. albicans, which has highlighted the importance of aspartate amino trans-
ferase in C. albicans biofilm development, and identified its potential as a therapeutic target for improving clinical 
management.
In order to avoid this limitation and focus on novel, promising, targets for improving the management of 
biofilm-based infections, we conducted an advanced network-based analysis. Using this approach, we found vari-
ous amino acids, pyruvate and fatty acid metabolism pathways to be central pathways upregulated in the HBF. The 
increased intracellular level of pyruvate, pentoses and amino acids in early biofilm phase contributes to increased 
biomass in maturation phase30. Fatty acids have diverse functions in the cells as they are important constituents 
of lipids, plays a role in energy storage, integrity and dynamics of cell membrane and adhesion to host cells31. 
Conversely, purine, starch and sucrose metabolic pathways were predominantly expressed in LBF.
Various amino acid pathways, including arginine, proline, purine, alanine, aspartate and glutamate metab-
olisms were shown to be considerably upregulated in the HBF. The exact regulatory mechanism behind this 
amino acid metabolism is not yet clear. It is known that amino acid starvation activates the general amino acid 
control (GCN) response, and that GCN4-regulated amino acid metabolism is required for normal biofilm for-
mation by C. albicans13. In response to amino acid starvation, GCN4 regulates a number of genes, which in turn 
activates amino acid biosynthesis and morphogenesis in C. albicans and Saccharomyces cerevisiae9. Interestingly, 
the AAT1 gene that encodes aspartate aminotransferase, was found to be a key member of different amino acid 
pathways that were upregulated in the HBF. AAT1 was shown to be a soluble protein in hyphae, and knocking 
out AAT1 gene does not impact C. albicans viability32,33. The mechanism of activation of AAT1 and its role in 
biofilm formation is not yet clear to us, but we hypothesise that this acts downstream of the GCN4 pathway. Our 
data suggests that it may have residual morphological effects, as also reported for GCN49, and this may interfere 
with biofilm stability as a result. However, further mechanistic studies are required to confirm this. Nevertheless, 
pharmacological inhibition of AAT was shown to significantly reduce the C. albicans biofilm biomass, confirming 
its apparent role in biofilm formation and its potential as an antifungal target. Our biochemical assay showed a 
significantly higher AAT level (P < 0.05) among HBF isolates compared to LBF, suggesting that AAT has the 
potential to be used diagnostically to differentiate the two phenotypes.
Collectively, using an integrated approach to analyse clinically important C. albicans isolates, we were able to 
link various metabolic pathways to defined biofilm phenotypes. A dedicated computational approach allowed us 
to dissect high-dimensional RNA-Seq output and to recover the essential pathway biology. The genes that were 
identified to be the key components were subsequently confirmed (AAT1, ACC1, SAD1 and XOG1) and validated 
(AAT1) in vitro experiments. AAT1 and ACC1 were found to be upregulated in HBF and SAD1 and XOG1 were 
upregulated in LBF. Previous studies have investigated the role of some of these genes in biofilm formation. For 
example, XOG1 gene shown to have no impact on cell wall glucan content of biofilm cells, nor it is necessary for 
filamentation or biofilm formation34, which is in agreement with our data. ACC1 encodes acetyl-coenzyme-A 
carboxylases, which have been shown to be upregulated in biofilm cells. Its transcription may indirectly depend 
on oxygen availability, but also on the availability of inositol in S. cerevisiae35.
Our ultimate aim from these studies and moving forward is to identify a potential target for biofilm diagnos-
tics and antifungal development. Here, we highlighted the importance of amino acid metabolism in the HBF. The 
key enzyme of this metabolism, AAT, was also shown to be a potential target for the management of biofilm-based 
infections. Future integrated OMICs approaches will support these investigations.
Figure 5. Biochemical validation of AAT enzyme activity levels in HBF and LBF isolates. Levels of the AAT 
enzyme activity in 24 h grown HBF (n = 5) and LBF (n = 5) biofilms were assessed using a colorimetric assay. 
The bar graph shows AAT activity standardised to biofilm biomass. *P < 0.05.
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Materials and Methods
Culture conditions and standardisation. This study utilised Candida albicans strain SC5314 and a series 
of routine patient anonymised clinical bloodstream isolates (n  =  30) collected under the approval of the NHS 
Scotland Caldicott Gaurdians, as part of candidaemia epidemiology surveillance study17,36. C. albicans clinical 
bloodstream isolates previously identified to have high biofilm formation (HBF [n = 15]) and low biofilm for-
mation (LBF [n = 15]) were used throughout this study17,36. Isolates were stored in Microbank® vials (Pro-Lab 
Diagnostics, Cheshire, UK) at − 80 °C until sub-cultured onto Sabouraud’s dextrose agar (SAB [Sigma-Aldrich, 
Dorset, UK]). Isolates were propagated in yeast peptone dextrose (YPD) medium (Sigma-Aldrich, Dorset, UK), 
washed by centrifugation and re-suspended in RPMI-1640 (Sigma-Aldrich, Dorset, UK) to 1 × 106 cells/mL, as 
described previously37. Biofilms were grown in polystyrene plates or 75 cm2 tissue culture flasks in RPMI for 24 h 
at 37 °C.
RNA extraction and sequencing. Following incubation, biofilms were washed with PBS before a cell 
scraper was used to dislodge the biomass, which was homogenised using a bead beater, and RNA extracted using 
the TRIzol™ (Life Technologies, Paisley, UK) method as described previously38. Total RNA was DNase (Qiagen, 
Crawley, UK) treated and purified using an RNeasy MiniElute clean up kit (Qiagen, Crawley, UK), as per man-
ufacturer’s instructions. RNA was quantified and quality assessed using a NanoDrop spectrophotometer (ND-
1000, ThermoScientific, Loughborough, UK). The integrity of the RNA was assessed using an agarose gel to 
visualise the two distinct rRNA bands. Each isolate was grown in triplicate and a minimum of 10 μ g of total RNA 
was submitted for each sample and sent for sequencing to The GenePool (Edinburgh, UK). RNA integrity was 
assessed using a Bioanalyzer where an RIN value > 7.0 was deemed acceptable for RNA-Seq using Illumina 50 
base pair sequencing.
Pre-processing of RNA-Seq data. The reads that had an overlap of at least 8 bp with the adapter sequence 
(Illumina TruSeq v3 i7) were filtered out using cutadapt v1.7.1 with default parameters39. Quality-trimming on 
the remaining reads was done using sickle v1.31 (available at https://github.com/najoshi/sickle) with an aver-
age quality score of 15 over a 5-bp sliding window. Reads that were trimmed by sickle to a length shorter than 
30 bp were discarded. Subsequently, reads originating from non-coding RNAs were filtered out using sortMeRNA 
v1.99-beta40 with default parameters and databases.
Candida albicans genome and its annotation. The diploid genome sequence of Candida albicans 
SC5314 (assembly 22) was downloaded (February 2015) from the Candida Genome Database45, http://www.
candidagenome.org/and was converted to a haploid genome by discarding one of the chromosomes in each 
homologous chromosome pair. This haploid reference was annotated using the C. albicans genes in the KEGG 
database21 as follows: (i) The nucleotide sequences of 14,661 C. albicans SC5314 genes in the KEGG database were 
clustered at 85% sequence identity using the USEARCH41 algorithm (-cluster_fast option). The resulting 7,281 
non-homologous genes were mapped to the haploid C. albicans genome using the UBLAST algorithm (E-value 
10−6, query coverage 0.95) to annotate the RNA-coding regions in the genome in the form of a GTF file using 
in-house scripts. Subsequently, STAR RNA-Seq aligner42 was used to generate index files for the haploid genome 
using the GTF annotations. The pre-processed reads were then aligned to the indexed genome using the STAR 
RNA-Seq aligner with default parameters.
Differential expression analysis. Following mapping, for each sample, the number of reads that were 
unambiguously mapped to a gene was estimated by parsing the STAR RNA-Seq alignment output by HTSeq43 
v.0.6.1 (default parameters). Next, an unpaired differential expression analysis (LBF vs HBF) using DESeq2 
v1.6.144 was performed with default settings as described in the package vignette. Briefly, the package normalizes 
read counts to account for different library sizes and uses negative binomial generalized linear models to deter-
mine a conservative set of genes that are differentially expressed across experimental conditions.
Functional annotation. We determined the Gene Ontology22 functional processes of significantly upreg-
ulated genes that showed a minimum 2-fold increase in their expression in the HBF and LBF. To do so, the list of 
genes were used as input for the GO Slim Mapper tool of the Candida Genome Database45 with the preselection of 
the following processes: biofilm formation, cell adhesion, cell budding, cell wall organization, cellular homeosta-
sis, filamentous growth, hyphal growth, interspecies interaction between organisms, pathogenesis, pseudohyphal 
growth, response to chemical, response to drug, response to stress, signal transduction and transport.
C. albicans gene network. The KEGG pathway maps of C. albicans SC5314 were used to create a global 
functional interaction network of C. albicans genes. To this end, gene relations defined in the individual pathways, 
such as acting on the same substrate, were used to derive the interactions between genes, which were then merged 
into a single network. The global gene network for the HBF-LBF comparison was then obtained by taking the 
intersection of genes in the global C. albicans network and those genes that were tested for differential expression, 
followed by the removal of non-interacting genes.
Identifying the key metabolic subnetwork. Following the works of Dittrich, et al.46 and May, et al.47, the 
computational analysis presented here aims at identifying the set of connected (i.e. interacting) C. albicans genes 
with the most significant deregulation across the LBF and HBF groups. In other words, the result is a subnetwork 
within the global C. albicans network, which contains the connected genes of most significant fold changes. This 
requires (i) the annotation of genes (nodes) in the global network with positive and negative numerical scores 
that reflect the significance of the difference in expression across conditions, followed by (ii) the application of 
a network search algorithm that can identify the maximum-scoring region in the network. In order to perform 
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these steps, first, we used the BioNet R package48 to fit a statistical model to the P value distribution of fold 
changes (see Supp. Fig. 2., for details, see Pounds and Morris49). Next, a false-discovery rate of 10−9 was used to 
determine a P value threshold (10−10), according to which, the statistical model was used to calculate positive 
and negative weights for genes with P values smaller and larger than the threshold, respectively. Once the genes 
(nodes) in the network were annotated with such numerical scores, the Heinz algorithm46 was used to calculate 
the maximum-scoring subnetwork that delineated the most significantly deregulated region in the larger net-
work. The subnetwork was visualised using the Cytoscape50 plugin eXamine51.
Validation of the RNA-Seq analysis. C. albicans clinical isolates exhibiting LBF (n  =  9) and HBF (n  =  9) 
were selected for the analysis of genes related to biofilm formation. Biofilms were grown and RNA was extracted 
as described elsewhere36. Next, cDNA was synthesised using High Capacity RNA to cDNA kit (Life Technologies, 
Paisley, UK) in a MyCycler PCR machine (Bio-Rad Laboratories, Hertfordshire, UK), following manufactur-
er’s instructions. The primers for the four selected genes from the KEGG pathway analysis are listed in Table 3. 
Cycle conditions consisted of 2 min at 50 °C, 10 min at 95 °C and forty cycles of 15 s at 95 °C and 60 s at 60 °C. All 
qPCR assays were performed in duplicate using MxProP Quantitative PCR machine and MxProP 3000 software 
(Stratagene, Amsterdam, Netherlands) and controls consisted of reactions in which reverse transcriptase template 
were absent. Gene expression was calculated using the Δ Ct method where the genes of interest were normalised 
to the housekeeping gene ACT1.
Validation of aminotransferase activity. Aspartate amino transferase enzyme activity was measured 
using a commercial assay kit (Sigma, Dorset, UK), by following the manufacturer’s instructions. To assess the 
impact of AAT inhibition on C. albicans biofilm formation, we used an inhibitor called aminoxyacetate (AOA 
[Sigma, Dorset, UK]). C. albicans clinical isolates (n = 12) were grown for 24 h in the presence of serially diluted 
concentration of AOA (ranging from 0 to 400 mg/L) in RPMI at 37 °C, with an untreated control included on 
each plate for comparison. After incubation, the biofilms were washed in PBS and their biomasses were quantified 
using a crystal violet technique previously described by our group17. Growth curve analysis was also performed 
for isolates grown in the presence of AOA (100 and 400 mg/L) by measuring absorbance at a wavelength of 
530 nm for 24 h in YPD and RPMI media. No significant change in endpoint growth levels were found in the 
presence of AOA at any tested concentrations, though a slight delay in growth rate in RPMI (data not shown).
Scanning Electron microscopy. C. albicans type strain SC5314 was grown directly onto Thermanox™ 
coverslips (Nunc, Roskilde, Denmark) for 24 h in the presence and absence of AOA (400 mg/L) After incubation 
period, biofilms were carefully washed with PBS and processed for SEM as previously described52. Briefly, sam-
ples were fixed in 2% paraformaldehyde, 2% glutaraldehyde, and 0.15% [wt/vol] alcian blue in 0.15 M sodium 
cacodylate (pH 7.4). The biofilms were sputter coated with gold and viewed under a JEOL JSM-6400 scanning 
electron microscope.
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